DIKUL - logo
E-viri
Recenzirano Odprti dostop
  • Thrombolysis in Myocardial ...
    Huang, Duo; Cheng, Yang-Yang; Wong, Yiu-Tung Anthony; Yung, See-Yue Arthur; Tam, Chor-Cheung Frankie; Chan, Ki-Wan Kelvin; Lam, Cheung-Chi Simon; Yiu, Kai-Hang; Hai, Jo Jo; Lau, Chu-Pak; Chan, Esther W; Chiang, Chern-En; Wong, Ka-Lam; Cheung, Tommy; Cheung, Bernard Man-Yung; Feng, Ying-Qing; Tan, Ning; Chen, Ji-Yan; Yue, Wen-Sheng; Hu, Hou-Xiang; Chen, Ling; Tse, Hung-Fat; Chan, Pak-Hei; Siu, Chung-Wah

    Circulation Journal, 03/2019, Letnik: 83, Številka: 4
    Journal Article

    Background: Patients who survive myocardial infarction (MI) are at risk of recurrent cardiovascular (CV) events. This study stratified post-MI patients for risk of recurrent CV events using the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS 2°P). Methods and Results: This was an observational study that applied TRS 2°P to a consecutive cohort of post-MI patients. The primary outcome was a composite endpoint of CV death, non-fatal MI, and non-fatal ischemic stroke. A total of 1,688 post-MI patients (70.3±13.6 years; male, 63.1%) were enrolled. After a mean follow-up of 41.5±34.4 months, 405 patients (24.0%) had developed a primary outcome (9.3%/year) consisting of 278 CV deaths, 134 non-fatal MI, and 33 non-fatal strokes. TRS 2°P was strongly associated with the primary outcome. The annual incidence of primary composite endpoint for patients with TRS 2°P 0 was 1.0%, and increased progressively to 39.9% for those with TRS 2°P ≥6 (HR, 27.6; 95% CI: 9.87–77.39, P<0.001). The diagnostic sensitivity of TRS 2°P for the primary composite endpoint was 76.3% (95% CI: 72.1–80.5%). Similar associations were also observed between TRS 2°P and CV death and non-fatal MI, but not non-fatal ischemic stroke. Conclusions: TRS 2°P reliably stratified post-MI patients for risk of future CV events.